Fran Lowry | Authors




Next gen EGFR targeting drug promising in NSCLC

December 29, 2010

Finding an effective treatment for all the complex iterations of cancer is akin to chasing an outlaw through a treacherous mountain range, in the estimation of Louis M. Weiner, MD, director of the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC.

Trastuzumab-DM1 delivers encouraging results in HER2+ breast cancer

December 29, 2010

Impressive results from an ongoing study of an anti-HER2 antibody-drug conjugate in HER2-positive metastatic breast cancer has already fast-tracked a phase III trial.Trastuzumab-DM1 (T-DM1) has demonstrated comparable results to standard treatment but with much less grade 3-4 toxicity in phase II trial results.

Novel HDAC inhibitor offers hope in heavily pretreated HL patients

December 09, 2010

Phase II study results are encouraging because this patient population generally sees a median of five prior lines of therapy including transplants, explained Jeffrey M. Besterman, MD, PhD, executive vice president and chief scientific officer for MethylGene, the developer of mocetinostat (MGCD0103).

Nilotinib Exerts Positive Effect in Early Chronic Phase Ph+ CML

December 07, 2010

At a median follow-up of 36 months, multiple survival rates were nearly perfect at 99%. The leader of the Italian study called the low number of treatment failures reassuring news as to the durability of nilotinib response at three years post-therapy